Minimal Change Disease Associated With Durvalumab

Affiliations

¹ Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
² Department of Respiratory Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
³ Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

Masataro G Toda et al. Kidney Int Rep. 2021.

. 2021 Sep 1;6(10):2733-2734.

doi: 10.1016/j.ekir.2021.08.021. eCollection 2021 Oct.

¹ Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
² Department of Respiratory Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
³ Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

No abstract available

References

1. Ohara G., Satoh H., Kurishima K. Paraneoplastic nephrotic syndrome in patients with lung cancer. Intern Med. 2009;48:1817–1820. - PubMed
1. Vaughan E., Connolly E., Hui M. Minimal change disease in a patient receiving checkpoint inhibition: another possible manifestation of kidney autoimmunity? Cancer Rep (Hoboken) 2020;3:e1250. - PMC - PubMed
1. Kitchlu A., Fingrut W., Avila-Casado C. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am J Kidney Dis. 2017;70:581–585. - PubMed
1. Brahmer J.R., Lacchetti C., Schneider B.J. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–1768. - PMC - PubMed
1. Gupta S., Cortazar F.B., Riella L.V. Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney. 2020;1:130–140. - PMC - PubMed